Vera Therapeutics Past Earnings Performance
Past criteria checks 0/6
Vera Therapeutics's earnings have been declining at an average annual rate of -33%, while the Biotechs industry saw earnings growing at 12% annually.
Key information
-33.0%
Earnings growth rate
94.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -94.4% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect
Jan 25Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove
Sep 06Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17
Aug 10Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth
Feb 16
Vera: Biotech With 3 Mid-Stage Programs With Potential For Success
Jan 19Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot
Jan 07We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth
Oct 25Vera Therapeutics soars 16% on three new favorable view from analysts
Jun 08Revenue & Expenses BreakdownBeta
How Vera Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -96 | 24 | 78 |
| 30 Sep 23 | 0 | -103 | 24 | 84 |
| 30 Jun 23 | 0 | -107 | 24 | 88 |
| 31 Mar 23 | 0 | -102 | 24 | 82 |
| 31 Dec 22 | 0 | -89 | 22 | 69 |
| 30 Sep 22 | 0 | -73 | 19 | 55 |
| 30 Jun 22 | 0 | -56 | 17 | 39 |
| 31 Mar 22 | 0 | -45 | 15 | 32 |
| 31 Dec 21 | 0 | -33 | 12 | 22 |
| 30 Sep 21 | 0 | -59 | 9 | 50 |
| 30 Jun 21 | 0 | -55 | 6 | 48 |
| 31 Mar 21 | 0 | -56 | 5 | 47 |
| 31 Dec 20 | 0 | -53 | 4 | 45 |
Quality Earnings: VERA is currently unprofitable.
Growing Profit Margin: VERA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VERA is unprofitable, and losses have increased over the past 5 years at a rate of 33% per year.
Accelerating Growth: Unable to compare VERA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VERA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: VERA has a negative Return on Equity (-94.4%), as it is currently unprofitable.